Tiziana CEO Kunwar Shailubhai discusses the company’s anti il6 technology to deliver drugs to lungs with Andrew Scott at Proactive Investors
Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO and chief scientific officer Kunwar Shailubhai discusses the recent excitement around inhalation and the direct delivery of drugs to lungs. ”It makes a lot of sense”, he says. Shailubhai says he’s pleased he’s covered this approach in his recent patent and in fact was one of the first to do […]
Mirriad Advertising #MIRI – Notice of analyst and investor webinar on May 12th
Stephan Beringer, CEO of Mirriad and John Pearson, Chairman, will be hosting a webinar for analysts and investors at 10:00am BST on 12 May 2020 to provide a briefing presentation following the release of Mirriad plc’s interim results. If you would like to attend, please contact Charlotte Street Partners at mirriad@charlottestpartners.co.uk to register and receive dial-in details. About Mirriad Mirriad ‘s […]
Cadence Minerals #KDNC – Total Voting Rights & Capital
Cadence Minerals (AIM/NEX: KDNC; OTC: KDNCY) notes that further to its announcement of 01 May 2020 and in accordance with the FCA’s Disclosure and Transparency Rule 5.6.1(R), the Company’s issued share capital will comprise 120,206,966 Ordinary Shares at 8am on 07 May 2020 where 8,749,998 Placing Shares and 3,995,000 Conversion Shares will be admitted to […]
Tiziana Life Sciences #TILS – Result of GM
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION At the General […]
Tiziana Life Sciences #TILS – Major shareholder increases stake
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : TIZIANA LIFE SCIENCES PLC […]
Cadence Minerals #KDNC – Macarthur Minerals (TSX-V: MMS) announces that Assays have been completed for infill drilling of the Lake Giles Iron Project.
Cadence Minerals (AIM/NEX: KDNC; OTC: KDNCY) is pleased to note that Macarthur Minerals (TSX-V: MMS) (“Macarthur”) has recently received the final XRF and Davis Tube Recovery (DTR) assays for the infill drilling program completed at its Lake Giles Iron Project near Kalgoorlie in Western Australia. The DTR assays confirm significant intersections of magnetite mineralisation with […]
Open Orphan Chairman Cathal Friel speaks to BRR Media re the new contract, other developments and the CEO’s departure
Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Rosie Riall at BRR Media after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study. Cathal also covers the channel pipeline, the hVIVO quarantine centre, flu and malaria vaccines and the planned departure of CEO Trevor Phillips.
Blencowe Resources (BRES) – New Research Initiation
Blencowe Resources, the recently relisted natural resources company focused on development of the Orom-Cross Graphite Project in Uganda, is pleased to advise that Align Research has today initiated research coverage on the Company. The initiation piece covers both an overview of operations and a review of the broader graphite market and sets an initial target […]
Open Orphan #ORPH & Cadence Minerals #KDNC on the Vox Markets podcast
Cathal Friel, Executive Chairman of Open Orphan (ORPH) talks about the major new contract they’ve signed with a US biotechnology company. Kiran Morzaria CEO of Cadence Minerals (KDNC) provides an update on operations at their Amapá project. Interview starts at 24 minutes 40 seconds. Link here to listen
Open Orphan #ORPH Exec Chairman Cathal Friel speaks to Proactive’s Andrew Scott about the new US biotech deal
Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study.